RUNX2 prompts triple negative breast cancer drug resistance through TGF-β pathway regulating breast cancer stem cells

RUNX2 prompts triple negative breast cancer drug resistance through TGF-β pathway regulating breast cancer stem cells

Triple-negative breast cancer (TNBC) stands out as the most aggressive subtype within the spectrum of breast cancer. The current clinical guidelines propose treatment strategies involving cytotoxic agents like epirubicin or paclitaxel. However, the emergence of acquired resistance frequently precipi...

Полное описание

Библиографические подробности
Главные авторы: Fengxu Lv, Wentao Si, Xiaodan Xu, Xiaogang He, Ying Wang, Yetian Li, Feifei Li
Формат: Статья
Язык:English
Опубликовано: Elsevier 2024-02-01
Серии:Neoplasia: An International Journal for Oncology Research
Предметы:
Triple negative breast cancer
Chemoresistance
Cancer stem cells
RUNX2
TGF-β
Online-ссылка:http://www.sciencedirect.com/science/article/pii/S1476558624000046

Internet

http://www.sciencedirect.com/science/article/pii/S1476558624000046

Схожие документы